HIV molecular immunology database
VPVWKEATTTLFCASDAKAY
|
gp160(42-61) | human epitope |
VPVWKEATTTLFCASDAKAY
|
gp160(42-61) | human epitope |
VPVWKEATTTLFCASDAKAY
|
gp160(42-61) | human epitope |
VPVWKEATTTLFCASDAKAY
|
gp160(42-61) | human epitope |
VPVWKEATTTLsrASDAKAY
|
gp160(42-61) | observed variant |
aPVWKEATTTLFCASDAKAY
|
gp160(42-61) | observed variant |
VPVWKEATTTLFrASDAKAY
|
gp160(42-61) | observed variant |
VPVWKEATTTLFCvSDAKAY
|
gp160(42-61) | observed variant |
VPVWKEATTTLFCAtDAKAY
|
gp160(42-61) | observed variant |
VPVWKEATTTLFyASDAKAY
|
gp160(42-61) | observed variant |
VPVWKEATTTpFCASDAKAY
|
gp160(42-61) | observed variant |
VPaWKEATTTLFCASDAKsY
|
gp160(42-61) | observed variant |
LFCASDAKAY
|
gp160(52-61) | A24 human epitope |
LFCASDAKAY
|
gp160(52-61) | A24 human epitope |
LFCASDAKAY
|
gp160(52-61) | A24 human epitope |
LFCASDAKAY
|
gp160(52-61) | A24 human epitope |
LFCASDAKAY
|
gp160(52-61) | A24 human epitope |
LFCASCAKAY
|
gp160(52-61) | A24, B38 human epitope |
LFCASDAKAY
|
gp160(52-61) | A*24:02 human epitope |
LFCASDAKAY
|
gp160(52-61) | A*24:02 human epitope |
LFCASDAKAY
|
gp160(52-61) | B*07 human epitope |
LFCASDAKAY
|
gp160(52-61) | B*08 human epitope |
LFCASDAKAY
|
gp160(52-61) | C*12 human epitope |
LFCASDAKAY
|
gp160(52-61) | C*16 human epitope |
LFCASDAKAY
|
gp160(52-61) | human epitope |
LFCASDAKAYDTEVHINVWAT
|
gp160(52-71) | human epitope |
LFCASDAKAYDTEVHINVWAT
|
gp160(52-71) | human epitope |
FCASDAKSY
|
gp160(53-61) | B*38:01 human epitope |
CASDAKAYDTEVHNV
|
gp160(54-68) | mouse epitope |
ASDAKAYETEVHNVWATH
|
gp160(55-72) | human epitope |
ASDAKAHDPEVHNVWATH
|
gp160(55-72) | human epitope |
ASDAKAHDPEVyNVWATH
|
gp160(55-72) | diminished response |
AKAYETEKHNVW
|
gp160(58-69) | human epitope |
KAYETEVHNVW
|
gp160(59-69) | A*23 human epitope |
KAYETEVHNVW
|
gp160(59-69) | A*34 human epitope |
KAYETEVHNVW
|
gp160(59-69) | A*36 human epitope |
KAYETEVHNVW
|
gp160(59-69) | B*37 human epitope |
KAYETEVHNVW
|
gp160(59-69) | B*44 human epitope |
KAYETEVHNVW
|
gp160(59-69) | B*57 human epitope |
KAYEKEVHNVW
|
gp160(59-69) | B*57:03, B*58:01 human epitope |
KAYETEVHNVW
|
gp160(59-69) | B*58 human epitope |
KAYETEVHNVW
|
gp160(59-69) | B*58:01 human epitope |
KAHDPEVHNVW
|
gp160(59-69) | B*58:01 human epitope |
KAHDPEVyNVW
|
gp160(59-69) | diminished response |
KAYDTEVHNVW
|
gp160(59-69) | human epitope |
KAYeTEVHNVW
|
gp160(59-69) | observed variant |
YETEVHNVW
|
gp160(61-69) | B*18 human epitope |
YkTEVHNVW
|
gp160(61-69) | observed variant |
YEkEVHNVW
|
gp160(61-69) | observed variant |
YgTEVHNVW
|
gp160(61-69) | observed variant |
YqTEVHNVW
|
gp160(61-69) | observed variant |
YEaEVHNVW
|
gp160(61-69) | observed variant |
YEaEVHsVW
|
gp160(61-69) | observed variant |
YETgiHNVW
|
gp160(61-69) | observed variant |
YETEaHNVW
|
gp160(61-69) | observed variant; replicative capacity is not abrogated; susceptible form |
YdTEaHNVW
|
gp160(61-69) | escape documented in this paper; replicative capacity/ fitness enhanced; observed variant |
hETEaHNVW
|
gp160(61-69) | observed variant |
YdTEVHNVW
|
gp160(61-69) | escape documented in this paper; replicative capacity/ fitness enhanced; observed variant |
YdiEVHNVW
|
gp160(61-69) | escape documented in this paper; observed variant |
YETEVHNVW
|
gp160(61-69) | B*18:01 human epitope |
YgTEVHNVW
|
gp160(61-69) | diminished response |
YETEaHNVW
|
gp160(61-69) | diminished response |
YdTEVHNVW
|
gp160(61-69) | diminished response |
YdTEaHNVW
|
gp160(61-69) | escape documented in this paper |
YETEVHNVW
|
gp160(61-69) | B*18:01 human epitope |
YgTEVHNVW
|
gp160(61-69) | diminished response |
YdTEVHNVW
|
gp160(61-69) | diminished response |
YdTEaHNVW
|
gp160(61-69) | diminished response |
YETEVHNVW
|
gp160(61-69) | B*18:01 human epitope |
YETEVHNVW
|
gp160(61-69) | B*18:01 human epitope |
YgTEVHNVW
|
gp160(61-69) | diminished response |
YdTEVHNVW
|
gp160(61-69) | diminished response |
YETEaHNVW
|
gp160(61-69) | susceptible form |
YdTEaHNVW
|
gp160(61-69) | diminished response |
DTEVHNVWATHACVP
|
gp160(62-76) | mouse epitope |
DTEVHNVWATHACVPTDPN
|
gp160(62-80) | human epitope |
KEVHNVWAT
|
gp160(63-71) | human epitope |
EVHNVWATHA
|
gp160(64-73) | A*26:03 human epitope |
EVHNiWATHA
|
gp160(64-73) | susceptible form |
EiHNVWATHA
|
gp160(64-73) | diminished HLA binding or increased off-rate; susceptible form |
EaHNVWATHA
|
gp160(64-73) | diminished HLA binding or increased off-rate; susceptible form |
EmHNVWATHA
|
gp160(64-73) | diminished HLA binding or increased off-rate; inferred escape |
EaHNiWATHA
|
gp160(64-73) | observed variant |
EkHNVWATHA
|
gp160(64-73) | diminished HLA binding or increased off-rate |
gVHNVWATHA
|
gp160(64-73) | observed variant |
EVHNmWATHA
|
gp160(64-73) | observed variant |
EVHNVsATHA
|
gp160(64-73) | observed variant |
EkHNiWATHA
|
gp160(64-73) | observed variant |
EkHNVsATHA
|
gp160(64-73) | observed variant |
EVHNVWAiHA
|
gp160(64-73) | observed variant |
EVHNVWATyA
|
gp160(64-73) | observed variant |
EVHNVWAkHA
|
gp160(64-73) | observed variant |
EVHNVWATqA
|
gp160(64-73) | observed variant |
ErHNVWATHA
|
gp160(64-73) | observed variant |
EVyNiWATHA
|
gp160(64-73) | observed variant |
EqHNVWATHA
|
gp160(64-73) | observed variant |
EqHiVWATHA
|
gp160(64-73) | observed variant |
EaHNVsATHA
|
gp160(64-73) | observed variant |
EgHNVWATHA
|
gp160(64-73) | observed variant |
EVHNaWATHA
|
gp160(64-73) | observed variant |
EVHNtWATHA
|
gp160(64-73) | observed variant |
EVHNVWgTfA
|
gp160(64-73) | observed variant |
gaHNiWATHA
|
gp160(64-73) | observed variant |
EaHNiWAsHA
|
gp160(64-73) | observed variant |
EaHdiWATHA
|
gp160(64-73) | observed variant |
EVHNVWATHv
|
gp160(64-73) | observed variant |
EVHNVWtTHA
|
gp160(64-73) | observed variant |
EmrsiWATHA
|
gp160(64-73) | observed variant |
EVHNVWATHACVPTD
|
gp160(64-78) | human epitope |
NIWATHACV
|
gp160(67-75) | A*02 human epitope |
NIWATHACV
|
gp160(67-75) | A*02:01 human epitope |
NIWATHACV
|
gp160(67-75) | A*02:01 transgenic mouse epitope |
NVWATHACV
|
gp160(67-75) | A2 human epitope |
NiWATHACV
|
gp160(67-75) | susceptible form |
NVWATrACV
|
gp160(67-75) | observed variant |
NiWATrACV
|
gp160(67-75) | observed variant |
NIWATHACV
|
gp160(67-75) | A2 human epitope |
NvWATHACV
|
gp160(67-75) | observed variant |
NIWATHACV
|
gp160(67-75) | A2 human epitope |
NIWATHACV
|
gp160(67-75) | A2 human epitope |
NvWATHACV
|
gp160(67-75) | non-susceptible form; susceptible form |
NVWATHACV
|
gp160(67-75) | human epitope |